Source:http://linkedlifedata.com/resource/pubmed/id/18440885
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2008-8-11
|
pubmed:abstractText |
The onset of scarring after injury may impede the regeneration and functional recovery of skeletal muscle. Matrix metalloproteinase-1 (MMP-1) hydrolyzes type I collagen and thus may improve muscle regeneration by resolving fibrotic tissue. We examined the effect of recombinant human MMP-1 on fibrosis in the lacerated gastrocnemius muscle of NOD/scid mice, allowing treatment potential to be ascertained in isolation from immune response. The efficacy of proMMP-1 and active MMP-1 were compared with or without poly(ethylene glycol) (PEG) modification, which was intended to increase the enzyme's stability. Active MMP-1 was most effective in reducing fibrosis, although treatment with proMMP-1 was also beneficial relative to controls. PEG-modified MMP-1 had minimal activity in vivo, despite retaining activity towards a thioester substrate. Moreover, the modified enzyme was inactivated by trypsin and subtilisin at rates comparable to that of native MMP-1. These results and those of computational structural studies suggest that modification occurs at the C-terminal hemopexin domain of MMP-1, which plays a critical role in collagen turnover. Site-specific modifications that spares catalytic and substrate binding sites while protecting susceptible proteolytic digestion sites may be beneficial. We conclude that active MMP-1 can effectively reduce muscle scarring and that its activity is related to the ability of the enzyme to digest collagen, thereby facilitating remodeling of the injured muscle.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1742-7061
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
4
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1411-20
|
pubmed:meshHeading |
pubmed-meshheading:18440885-Animals,
pubmed-meshheading:18440885-Fibrosis,
pubmed-meshheading:18440885-Humans,
pubmed-meshheading:18440885-Matrix Metalloproteinase 1,
pubmed-meshheading:18440885-Mice,
pubmed-meshheading:18440885-Mice, SCID,
pubmed-meshheading:18440885-Muscle, Skeletal,
pubmed-meshheading:18440885-Recombinant Proteins,
pubmed-meshheading:18440885-Treatment Outcome
|
pubmed:year |
2008
|
pubmed:articleTitle |
Matrix metalloproteinase-1 treatment of muscle fibrosis.
|
pubmed:affiliation |
McGowan Institute for Regenerative Medicine, University of Pittsburgh, 100 Technology Drive, Suite #200, Pittsburgh, PA 15219, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.
|